Docetaxel trihydrate

Get a Price/Quote

MOQ : 1 Kilograms

Docetaxel trihydrate Specification

Molecular Weight
861.9 Grams (g)

Appearance
white crystalline powder

Usage
Docetaxel trihydrate is the trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. It has a role as an antineoplastic agent. It is a hydrate and a secondary alpha-hydroxy ketone.

Melting Point
>190° C

Molecular Formula
C43H59NO17

Docetaxel trihydrate Trade Information

Minimum Order Quantity
1 Kilograms

Payment Terms
Cash Advance (CA), Cash in Advance (CID)

Supply Ability
500 Kilograms KG Per Month

Delivery Time
2-8 Week

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
Carton and Poly Bag.

Main Export Market(s)
Western Europe, Eastern Europe, Middle East, South America, Australia, Asia, Central America, North America, Africa

Main Domestic Market
All India

About Docetaxel trihydrate

Docetaxel trihydrate is a potent antineoplastic agent presented as a white crystalline powder with a molecular formula of C43H59NO17 and a molecular weight of 861.9 grams. This trihydrate form of docetaxel is highly effective in treating various forms of cancer, including breast, ovarian, non-small cell lung cancer, and hormone-refractory metastatic prostate cancer when combined with prednisone or prednisolone. With a melting point exceeding 190 C, it ensures high thermal stability. This compound also exhibits properties as a hydrate and a secondary alpha-hydroxy ketone, enhancing its usability in various pharmaceutical applications. Docetaxel trihydrate is widely recognized for its role in cancer treatment protocols, delivering targeted efficacy while supporting research and therapeutic advancements in oncology.

FAQs of Docetaxel trihydrate:

Q: What is Docetaxel trihydrate used for?

A: Docetaxel trihydrate is used for treating breast, ovarian, non-small cell lung cancer, and hormone-refractory metastatic prostate cancer (in combination with prednisone or prednisolone).